The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host by Calvo-Pinilla, Eva et al.
Contents lists available at ScienceDirect
Antiviral Research
journal homepage: www.elsevier.com/locate/antiviral
The immunogenicity of recombinant vaccines based on modiﬁed Vaccinia
Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens
depends on the levels of expressed VP2 protein delivered to the host
Eva Calvo-Pinillaa,b, Simon Gubbinsa, Peter Mertensa, Javier Ortegob, Javier Castillo-Olivaresa,∗
a The Pirbright Institute, Ash Road, Pirbright, Surrey, GU24 0NF, UK
b INIA-CISA, 28130, Valdeolmos, Madrid, Spain
A R T I C L E I N F O
Keywords:
African horse sickness
Vaccinia
MVA
VP2
A B S T R A C T
African horse sickness (AHS) is a lethal equine disease transmitted by Culicoides biting midges and caused by
African horse sickness virus (AHSV). AHS is endemic to sub-Saharan Africa, but devastating outbreaks have been
recorded periodically outside this region. The perceived risk of an AHS outbreak occurring in Europe has in-
creased following the frequent epidemics caused in ruminants by bluetongue virus, closely related to AHSV.
Attenuated vaccines for AHS are considered unsuitable for use in non-endemic countries due bio-safety
concerns. Further, attenuated and inactivated vaccines are not compatible with DIVA (diﬀerentiate infected from
vaccinated animals) strategies. All these factors stimulated the development of novel AHS vaccines that are safer,
more eﬃcacious and DIVA compatible.
We showed previously that recombinant modiﬁed Vaccinia Ankara virus (MVA) vaccines encoding the outer
capsid protein of AHSV (AHSV-VP2) induced virus neutralising antibodies (VNAb) and protection against AHSV
in a mouse model and also in the horse. Passive immunisation studies demonstrated that immunity induced by
MVA-VP2 was associated with pre-challenge VNAb titres in the vaccinates. Analyses of the inoculum of these
MVA-VP2 experimental vaccines showed that they contained pre-formed AHSV-VP2.
We continued studying the inﬂuence of pre-formed AHSV-VP2, present in the inoculum of MVA-VP2 vaccines,
in the immunogenicity of MVA-VP2 vaccines. Thus, we compared correlates of immunity in challenged mice that
were previously vaccinated with: a) MVA-VP2 (live); b) MVA-VP2 (live and sucrose gradient puriﬁed); c) MVA-
VP2 (UV light inactivated); d) MVA-VP2 (UV light inactivated and diluted); e) MVA-VP2 (heat inactivated); f)
MVA-VP2 (UV inactivated) + MVA-VP2 (puriﬁed); g) MVA-VP2 (heat inactivated) + MVA-VP2 (puriﬁed); and
h) wild type-MVA (no insert). The results of these experiments showed that protection was maximal using MVA-
VP2 (live) vaccine and that the protection conferred by all other vaccines correlated strongly with the levels of
pre-formed AHSV-VP2 in the vaccine inoculum.
1. Introduction
African horse sickness (AHS) is an arthropod-borne viral disease of
solipeds transmitted by haematophagus insects of the genus Culicoides,
the horse being the most severely aﬀected species. The disease is caused
by African horse sickness virus (AHSV), a member of the genus
Orbivirus, family Reoviridae, closely related to bluetongue virus (BTV).
The non-enveloped 55–70 nm AHSV spherical virion consists of a triple-
layered capsid surrounding ten double-stranded RNA segments and
three proteins involved in viral replication (VP1, VP4 and VP6, encoded
by segments 1, 4 and 9 respectively) (Roy et al., 1994; Manole et al.,
2012). The inner capsid protein VP3, encoded by segment 3, forms the
icosahedral scaﬀold to which trimers of the conserved VP7 protein
bind. The outer capsid is formed by two major structural proteins, VP2
and VP5 (encoded by segments 2 and 6 respectively), involved in cell
attachment and entry. VP2 is the most variable antigen of AHSV, de-
termines serotype formation (Burrage et al., 1993) and contains most of
the virus neutralising antibody (VNAb) epitopes identiﬁed so far
(Bentley et al., 2000; Burrage et al., 1993; Martinez-Torrecuadrada
et al., 1999).
To date no eﬀective treatment exists for AHS and, consequently,
control of the disease relies on vaccination, control of animal move-
ments and prevention of bites by Culicoides midges. Live attenuated
AHS vaccines (LAV) have been in use in Africa for almost 100 years and
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permitted the subsistence of horses in that part of the world (Coetzer
and Guthrie, 2004; Mellor and Hamblin, 2004; von Teichman and Smit,
2008). There are nine diﬀerent serotypes of AHS virus (AHSV) and
protective immunity is long-lived but serotype-speciﬁc. Despite their
apparent eﬃcacy, the use of LAV presents a series of bio-safety con-
cerns, especially in non-endemic countries, which arise from the ability
of vaccine viruses to replicate in vivo and to exchange their genome
segments with other vaccine or ﬁeld AHS viruses. Recent studies in-
dicate that outbreaks of AHS occurring in the Western Cape Province of
South Africa between 2004 and 2014 may have resulted from re-as-
sortment events involving vaccine strains of serotype 1 (Weyer et al.,
2016).
Over the last 30 years much attention has been given to the de-
velopment of safer alternative AHS vaccines and a number of diﬀerent
approaches have been explored. These included the use of inactivated
AHSV (House et al., 1994; Lelli et al., 2013), baculovirus-expression of
AHSV capsid proteins (Roy, 1996), plasmid DNA vaccines (Romito
et al., 1999) or poxvirus expression vectors (Alberca et al., 2014;
Castillo-Olivares et al., 2011; de la Poza et al., 2013; Guthrie et al.,
2009). In previous studies we showed that recombinant modiﬁed
Vaccinia Ankara (MVA) viruses expressing AHSV-VP2 induced VNAb
and complete clinical protection in a mouse model and in the equine
species (Alberca et al., 2014; Castillo-Olivares et al., 2011; de la Poza
et al., 2013).
There is evidence suggesting that cell-mediated immune responses
play an important role in AHS immunity. Cell-mediated immune re-
sponses have been detected in horses immunized with live attenuated
vaccines (Pretorius et al., 2012) or recombinant Canarypox viruses
expressing VP2 and VP5 (El Garch et al., 2012) and, more recently, in
interferon alpha receptor gene knock-out mice (IFNAR −/−) after
vaccination with MVA VP2/NS1 (de la Poza et al., 2013). However, we
demonstrated that the eﬀector mechanisms of immunity of MVA-VP2
vaccination in mice are mediated mainly by antibodies (Calvo-Pinilla
et al., 2014, 2015).
Recombinant MVA vaccine viruses are replication-deﬁcient in
mammalian cells and clearance of MVA and its genes occurs rapidly
following inoculation (Altenburg et al., 2014). Despite the transient
expression of MVA encoded proteins within the vaccinated host, re-
combinant MVA vaccines eﬃciently induce cellular and humoral im-
munity (Drexler et al., 2004; Sutter et al., 1994). Thus, induction of
AHSV-VP2-speciﬁc antibody responses after MVA-VP2 vaccination is
thought to depend on expression of VP2 protein from MVA-VP2 in-
fected cells.
In our previous studies, MVA-VP2 vaccines were administered as
MVA-VP2-infected DF-1 cell lysates. Thus, pre-formed VP2 was be-
lieved to be present in the inoculum of these vaccines. In this paper, we
describe the results of experiments aimed at determining the role that
both pre-formed VP2, and VP2 synthesised de novo from MVA-VP2 in-
fected host cells, play in the immunogenicity of MVA-VP2 vaccines.
2. Materials and methods
2.1. Viruses and cells
Vero cells (ATCC, Cat. No. CCL-81) and Chicken embryo ﬁbroblast
(DF-1) (ATCC, Cat. No. CRL-12203) were grown in high glucose
Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with 2mM
glutamine, penicillin (100 units/ml), streptomycin (100 μg/ml) and
10% foetal calf serum (FCS). AHSV serotype 4 (AHSV-4, Madrid/87)
was grown in Vero cells and MVA viruses (wild type-MVA and MVA-
VP2) grown in DF-1 cells. Virus stocks were generated by infection of
sub conﬂuent cells using a multiplicity of infection (MOI) of 0.1. When
a total cytopathic eﬀect (CPE) was visible, the cells and supernatants
were harvested and centrifuged. The virus was released from the cells
by three freeze/thaw cycles, sonication and then titrated by plaque
assay.
2.2. MVA-VP2 vaccine preparations
Various MVA-VP2 vaccine preparations were used:
a) MVA-VP2 (live): MVA-VP2, expressing AHSV-4 VP2, was previously
described (Castillo-Olivares et al., 2011; Chiam et al., 2009) and was
bulked up for this study in DF-1 cells and subsequently used as a cell
lysate.
b) MVA-VP2 (UV) was obtained by exposure of 1ml aliquots of MVA-
VP2 dispensed on a p100 tissue culture plate to 254 nm wavelength
UV light for 40min. UV irradiation was achieved by placing the
plates at 3 cm below a TUV T8 lamp (Philips).
c) MVA-VP2 (HI), was heat-inactivated by heating 100 μl MVA-VP2
aliquots in a thermal block for 15min at 56 °C.
d) MVA-VP2 (SGP) is a sucrose-gradient-puriﬁed MVA-VP2 prepara-
tion obtained as follows. A volume of 20ml of MVA-VP2 was
overlaid carefully on top of 20ml of a sterile 36% (w/w) solution of
sucrose in PBS using 40ml ultra-clear centrifuge tube (Beckmann).
The samples were centrifuged for 1.5 h at 300000 g and 4 °C in a SW
28 rotor. The pellets were re-suspended thoroughly in 0.5ml sterile
PBS and sonicated brieﬂy before titration.
2.3. MVA-VP2 inactivation test
MVA-VP2 (HI) and MVA-VP2 (UV) were tested for infectivity using
MVA-VP2 (live) as a positive control. All three preparations were in-
oculated (MOI of 1) into DF-1 cell cultures. After an adsorption period
of 1.5 h cells were washed and medium was replaced. After 48 h, in-
fected cells were washed three times with PBS and RNA was extracted
from the cells using Trizol reagent (Invitrogen) according to the method
recommended by the manufacturer.
Reverse transcription-PCR (RT-PCR) was used to detect mRNA from
AHSV-4 genome segment 2 (coding for VP2 protein) in DF-1 cells in-
cubated with live and inactivated MVA-VP2. Oligonucleotide primers
used to amplify a segment of 900 bp were: a) forward primer: 5′-CGC
CCGGGATGGCGTCCGAGTTTGGAATATTG-3´; and b) reverse primer:
5′-CGCCCGGGCTACCCCTGCTTATCACCTGCTGA-3´.
RNA was denatured in the presence of a reverse VP2 gene-speciﬁc
primer and dNTP mix by heating to 65 °C for 5min. A mix of RT buﬀer,
MgCl2 and Reverse Transcriptase (200 U/μL) was added and the reac-
tion was incubated for 1 h at 50 °C. Ampliﬁcation of the VP2 gene was
performed by PCR using PCR Buﬀer II (Invitrogen), dNTPs, speciﬁc
primers (forward and reverse primers), MgCl2 solution, AmpliTaq DNA
Polymerase (Invitrogen), and cDNA template. Ampliﬁcation cycle
parameters were: 94 °C for 2min (1×); 94 °C for 45 s, 55 °C for 1min,
and 72 °C for 2min (30×); 94 °C for 15min (1×).
2.4. Western blot
Immunoblotting was performed as described previously (Chiam et al.,
2009). Samples were mixed 1:1 with 2× Laemmli sample buﬀer and
12 μL were loaded in each well of polyacrylamide gels. Three im-
munogenic AHSV-4 VP2-derived KLH-conjugated peptides (NH2-KKKEE-
GEDDTARQEIRKAWC-COOH; NH2-NKGKWKEHIKEVTEKLKKA-COOH;
NH2-DMNEKQKPYFEFEYDDFKPC-COOH) were selected to obtain a VP2-
speciﬁc rabbit polyclonal antibody from a commercial source (GenScript).
This antibody was used at a 1:400 dilution. A goat anti-rabbit peroxidase
(Bio-Rad) was used at a dilution of 1:10000.
2.5. Mice
Seven-week-old, female, Type I interferon receptor KO A129 IFNAR
(−/−) mice were purchased from B&K Universal. The animals were
rested for about a week before the experiments were performed in the
animal facilities of the Centro de Investigación en Sanidad Animal
(INIA-CISA). All protocols for animal use were approved by the Ethical
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Committee of the Centre for Animal Health Research (CISA-INIA)
(Permit number: PROEX 039/15) in strict accordance with the Spanish
National Royal Decree (RD1201/2005), EU guidelines 2010/63/UE
about protection of animals used for experimentation and other scien-
tiﬁc purposes, and the Spanish Animal Welfare Act 32/2007.
2.6. Vaccination of animals
Mice (n=5) were inoculated twice with 107 pfu/mouse (or
equivalent in the case of inactivated vaccines) of each vaccine pre-
paration for the ﬁrst experiment. For the second experiment, 3 groups
of mice (n=5) were vaccinated with 107, 108 or 5×108 pfu/mouse of
puriﬁed MVA-VP2. All immunisations were performed at day 0 and 21
by the intra-peritoneal route. Sera were collected from the sub-
mandibular vein at 2 weeks after the second vaccination for serological
analysis.
2.7. Plaque reduction neutralization test (PRNT)
Serial dilutions of mouse sera were incubated with 100 TCID50 of
AHSV-4 for 1 h at 37 °C. Then, samples were inoculated into one well
each of 12-well plates containing conﬂuent monolayers of Vero cells.
Following incubation for 1 h at 37 °C in 5% CO2 an agar overlay
(DMEM, 10% FBS, 0.4% agar) was added and plates incubated further
for 4 days at 37 °C in 5% CO2. Plaques were visualized with a counter-
stain solution (2% crystal violet, 10% formaldehyde, PBS). PRNT titre
was calculated as the reciprocal (log10) of the highest dilution of serum
that neutralised 50% of the control virus input.
2.8. Challenge with AHSV
Two weeks after the second vaccination, mice from the ﬁrst ex-
periment were infected with 106 TCID50 of AHSV-4 per mouse ad-
ministered by the sub-cutaneous route. Animals were monitored twice a
day after challenge.
2.9. Clinical signs and viraemia
Clinical scoring was performed as described previously (Calvo-
Pinilla et al., 2015). Mice were humanely euthanized when they
showed severe clinical signs (weight loss, dehydration, frequent
hunching, severe conjunctivitis or any other condition that prevented
food or water intake).
Whole-EDTA-blood samples were collected from the submandibular
vein at diﬀerent days post infection to analyse viraemia. Blood cells
were lysed with water before performing plaque assays on Vero cells as
described previously (Castillo-Olivares et al., 2011).
2.10. Statistical analysis
In the ﬁrst experiment, diﬀerences in survival amongst groups of
mice receiving each vaccine were compared using log-rank tests.
Clinical scores in groups of mice receiving each vaccine were compared
using Kruskal-Wallis tests. Diﬀerences between groups were then ex-
plored using post hoc Wilcoxon rank-sum tests. Diﬀerences in viraemia
amongst groups of mice receiving each vaccine were assessed using
linear mixed models with log10 pfu + 1 as the response variable, days
post infection (as a factor) and group as ﬁxed eﬀects and mouse as a
random eﬀect. Model selection proceeded by stepwise deletion of non-
signiﬁcant terms (as judged by the Akaike information criterion)
starting from a model including days post infection and group as main
eﬀects. In the second experiment, the relationship between vaccine
dose and PRNT50 titre was explored using linear regression with log10
PRNT50 titre as the response variable and log10 dose as the explanatory
variable. A signiﬁcance level of P=0.05 was used in all analyses. All
methods were implemented in R version 3.2.1 (R Core Team 2015).
3. Results
In order to investigate the immunogenicity of MVA-VP2 vaccines in
relation to pre-formed AHSV-VP2 present in the inoculum, we con-
ducted two vaccination experiments using various MVA-VP2 vaccine
preparations. In the ﬁrst vaccination experiment we vaccinated 8
groups of 5 mice with either of the following: a) MVA-VP2 (live); b)
MVA-VP2 (SGP); c) MVA-VP2 (UV); d) MVA-VP2 (UV 1/4) prepared by
diluting MVA-VP2 (UV) in DMEM; e) MVA-VP2 (HI); f) MVA-VP2
(UV) + MVA-VP2 (SGP); g) MVA-VP2 (HI) + MVA-VP2 (SGP); and h)
wild type-MVA (no insert). Following vaccination, animals were chal-
lenged with AHSV-4 and protective immunity assessed. In the second
experiment, we vaccinated 3 groups of 5 mice with either 107 pfu/
mouse; 108 pfu/mouse or 5× 108 pfu/mouse of MVA-VP2 (SGP). Sera
were obtained from these animals after vaccination and VNAb titres
determined.
Some of these MVA-VP2 vaccines were generated by inactivating
the infectivity of MVA-VP2 cell lysate stocks by exposure to heat or UV
light. Therefore, the immunogenicity of these vaccines would rely only
on the presence of pre-formed AHSV-VP2 in the inoculum and not on
VP2 protein synthesised de novo from MVA-VP2 infected host cells.
3.1. Inactivation of MVA-VP2 (HI) and MVA-VP2 (UV)
Both inactivated MVA-VP2 vaccines did not produce cytopathic
eﬀect in DF-1 cell cultures after an incubation period of 5 days. In order
to corroborate that inactivation of infectivity was successful and that
live MVA-VP2 virus was not present in the inoculum of MVA-VP2 (HI)
and MVA-VP2 (UV) vaccines, fresh DF-1 cell cultures were inoculated
with MVA-VP2 (HI) or MVA-VP2 (UV) and 48 h later VP2-mRNA de-
tection was performed by RT-PCR. PCR products of the expected size
could only be obtained from MVA-VP2 (SGP) and positive control MVA-
VP2 (live) infected cultures (Fig. 1). Additional experiments (not
shown) indicated that total MVA-VP2 inactivation was achieved after
UV (λ 254 nm) exposure for 40min or by heat treatment at 56 °C for
15min.
3.2. Antigenicity of AHSV-VP2 present in the inoculum
All the vaccine preparations used in the ﬁrst mouse experiment
were analysed for the presence of VP2 in the inoculum by immuno-
blotting with VP2-speciﬁc rabbit polyclonal antisera. The results in-
dicated that, with the exception of MVA-VP2 (SGP) and MVA (wt), all
samples showed a clear band of approximately 116 kDa, which corre-
sponds to monomers of AHSV-VP2 (Fig. 2).
Fig. 1. Inactivation of MVA-VP2 by heat or UV irradiation. Agarose gel
electrophoresis of RT-PCR product of the AHSV-VP2 gene transcripts. DF-1 cells
were infected with live, puriﬁed, heat or UV irradiated MVA-VP2 and 48 h later,
VP2-mRNA detection was performed by RT-PCR.
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3.3. Vaccination and challenge experiment with live and inactivated MVA-
VP2 vaccines
Protective immunity against AHSV-4 conferred by each of the MVA-
VP2 vaccine preparations was assessed in a vaccination and challenge
experiment.
3.3.1. Antibody responses following vaccination
Determination of VNAb titres against AHSV-4 of post-vaccination
(day 35) sera showed that all MVA-VP2 vaccinates developed VNAb.
However, there were signiﬁcant diﬀerences between some groups
(Fig. 3). Highest values were recorded for MVA-VP2 (live) vaccinates
(PRNT50= 2.10), followed by those obtained from all groups that were
vaccinated with preparations containing un-diluted inactivated MVA-
VP2 (PRNT50 titres ranging between 1.52 and 1.75). As expected, sera
from MVA-VP2 (1/4 UV) vaccinates showed PRNT50 titres just below
the positive cut-oﬀ value of the assay (PRNT50= 0.99). Similar values
were recorded for MVA-VP2 (SGP) vaccinates (PRNT50= 1.03). The
data collectively suggest that the presence of pre-formed AHSV-VP2 in
the inactivated MVA-VP2 vaccines played an important role in their
capacity to induce a VNAb response and that the immunogenicity was
reduced when the pre-formed VP2 in the inoculum was diluted or re-
moved from the inoculum of live MVA-VP2 vaccines (at the dose of
107 pfu/mouse).
3.3.2. Protection against AHSV-4 challenge
All vaccinates exhibited survival rates of 100% (ﬁve out of ﬁve mice
surviving), except those receiving MVA-VP2 (SGP) and MVA-VP2 (¼
UV) (both 80%, four out of ﬁve mice surviving). As expected, all MVA
(wt) vaccinated mice succumbed to AHSV-4 challenge. Survival was
signiﬁcantly (P < 0.001) lower in mice receiving wild-type MVA
compared with mice receiving any of the other vaccines.
Clinical scores (Fig. 4) diﬀered signiﬁcantly amongst groups
(P < 0.001), they are in line with survival rates and can be ranked in
decreasing order as follows: MVA (wt) a>MVA-VP2 (1/4 UV) b >
MVA-VP2 (SGP) b > MVA-VP2 (HI) c > MVA-VP2 (UV) c > MVA-
VP2 (SGP) + MVA-VP2 (UV) cd > MVA-VP2 (SGP) + MVA-VP2 (HI)
d > MVA-VP2 (live) d (where groups share a common superscripted
letter they do not diﬀer signiﬁcantly (P > 0.05)).
Analysis of viraemia data (Fig. 5) show that AHSV could not be
isolated from the blood of MVA-VP2 (live) vaccinated mice and that
groups vaccinated with preparations containing inactivated MVA-VP2
Fig. 2. Presence of AHSV-VP2 protein in the MVA-
VP2 vaccines’ preparations. Immunoblotting of
vaccine inoculum (left panel: ﬁrst vaccination ex-
periment; right panel: second vaccination experi-
ment) was performed using a VP2-speciﬁc rabbit
polyclonal antibody following SDS-PAGE separation
of proteins. Arrowhead indicates the expected size of
AHSV-4 VP2.
Fig. 3. Virus neutralizing antibody (VNAb) re-
sponses to AHSV in vaccinated mice. Serum VNAb
were determined by PRNT. Titers were assigned ar-
ithmetically as the dilution of serum that gave a 50%
neutralization endpoint and expressed as log10 values.
Each bar represents the mean of antibody titers of in-
dividual serum samples collected on day 35 post-im-
munization. Error bars represent the standard deviation
within the samples.
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(HI or UV) presented very low titre viraemia and only in some in-
dividuals. In contrast, the levels of AHSV in blood of MVA-VP2 (SGP)
and MVA-VP2 (1/4 UV) vaccinates were more elevated and occurred in
all individuals. As expected, blood samples from all negative controls
contained AHSV to high titres. Levels of viraemia diﬀered signiﬁcantly
(P < 0.001) amongst mice receiving diﬀerent vaccines. More pre-
cisely, vaccinates could be divided into a low viraemia category [MVA-
VP2 (live), MVA-VP2 (UV), MVA-VP2 (HI), MVA-VP2 (SGP) + MVA-
VP2 (UV) > MVA-VP2 (SGP) + MVA-VP2 (HI)] and a high viraemia
category [MVA-VP2 (1/4 UV), MVA-VP2 (SGP) and MVA (wt)]. Groups
within each category do not diﬀer statistically in the levels of viraemia
that they presented (P > 0.05).
Collectively the results from the challenge show that groups vacci-
nated with MVA-VP2 (SGP) and MVA-VP2 (1/4 UV) displayed low le-
vels of clinical protection against AHSV-4, and this correlated with the
levels of viraemia displayed by the animals. From the data it can be
inferred that the levels of protection observed in the animals also cor-
related with the presence of pre-formed VP2 in the inoculum of the
vaccines. MVA-VP2 (1/4 UV) presented a weak western blot signal
corresponding to AHSV-VP2 and this was almost non-existent in the
MVA-VP2 (SGP) lane (Fig. 2). When the MVA-VP2 (SGP) vaccine was
supplemented with inactivated MVA-VP2 cell lysates, the induction of
VNAb and protection against clinical signs, lethality and viraemia were
much higher than that induced by the non-supplemented MVA-VP2
(SGP) vaccine. Therefore, it appears that the presence of AHSV-VP2 in
the inoculum was a determining factor of immunogenicity of MVA-VP2
vaccines in this study. However, the results also seem to indicate and
that the de novo synthesis of VP2 in MVA-VP2 infected host cells plays
an additional role in immunogenicity since MVA-VP2 (live) vaccines
induced the highest protection levels in this study.
3.4. Dose-response vaccination experiment with MVA-VP2 (SGP)
The previous experiment indicated that the immunogenicity of
MVA-VP2 vaccines relies on the total mass of VP2 protein that is pre-
sented to the immune system following inoculation of the vaccine. The
VP2 protein in the inoculation site of the vaccinated animals originates
from two sources: a) pre-formed in the inoculum; and/or b) expressed
from MVA-VP2-infected host cells. In MVA-VP2 (SGP) vaccinated ani-
mals, VP2 is almost exclusively derived ‘de novo’ from MVA-VP2 (SGP)-
infected host cells since the inoculum is virtually free from VP2. Since
we have observed that an MVA-VP2 (SGP) vaccination dose of 107 pfu/
mouse induced a very poor VNAb response, a dose-response experiment
was conducted to determine if serum VNAb titres could be induced at
all by increasing the dose of the MVA-VP2 (SGP) vaccine.
Thus, 3 groups of mice were vaccinated with MVA-VP2 (SGP) using
doses of 107, 108 or 5× 108 pfu/mouse and the post-vaccination sera
subjected to PRNT testing. The mean PRNT titres of vaccinated mouse
sera were 1.05, 1.33 and 1.67 for the 107, 108 and 5×108 dose groups,
respectively. Statistical analysis of the data demonstrated a strong
correlation between dose and serum titres (P < 0.001), with every one
log increase in dose resulting in a 0.36 (95% conﬁdence interval: 0.28
to 0.44) increase in log10 PRNT titre. These data suggest that whilst live
MVA-VP2 vaccines containing cell lysates rely on the pre-formed VP2
for inducing a protective VNAb response, de novo synthesis of VP2 from
host cells plays also a role in MVA-VP2 immunogenicity. The im-
munoblotting experiment performed with the MVA-VP2 (SGP) vaccines
(Fig. 2, right panel) showed that the levels of VP2 present in the in-
oculum of MVA-VP2 (SGP), even at the highest dose (5× 108 pfu/
mouse), were lower than those of the MVA-VP2 (1/4 UV), which in-
duced a very low VNAb titre in the ﬁrst vaccination experiment. This
indicates that the positive correlation between VNAb titre and the dose
of MVA-VP2 (SGP) is probably associated with the increased expression
of VP2 in cells of the vaccinated animal. This hypothesis is consistent
with results of immunoﬂuorescence experiments performed on MVA-
VP2 infected DF-1 cells showing that the numbers of cells expressing
VP2 increase proportionally to multiplicity of MVA-VP2 infection (data
not shown).
4. Discussion
Recombinant MVA viruses have been used experimentally for the
prevention of infectious diseases both in humans and in a large variety
of animal species (Altenburg et al., 2014; Gilbert, 2013; Moyo et al.,
2017; Zhou and Sullivan, 2015). MVA vaccines rely on the expression of
relevant immunogenic ‘foreign’ protein genes which are artiﬁcially in-
serted into their genome. The starting point of the immune response
following inoculation of an MVA vaccine is the presentation of these
immunogenic molecules to the immune system of the vaccinated host.
The induction of protective B-cell and T-cell immune responses by
means of recombinant MVA virus vaccination has been extensively
described in the literature. MVA based vaccines have the ability to in-
duce both arms of the adaptive immune response. Indeed, MVA ex-
pressed antigens within ‘professional’ antigen presenting cells of the
vaccinated host can be processed via the endogenous and cross-pre-
sentation pathways to prime an eﬃcient T cell response. For induction
of an antibody response following vaccination it is necessary that B-cell
receptors bind to the foreign antigen. However, detailed studies on the
mechanisms underlying the induction of antibody responses by re-
combinant MVA vaccination are not abundant. Some experiments
suggest that targeting the foreign antigen to the secretory pathway can
lead to improved antibody induction (Yang et al., 1997), whilst others
describe strong antibody responses to antigens that are anchored to the
cell membrane (Bruder et al., 2010).
Fig. 4. Clinical score index after challenge. The clinical signs were recorded daily for 14 days. The lines within the box represents the mean of clinical score index
within the group. Error bars represent the standard deviation.
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We have shown previously that recombinant AHSV vaccines based
on expression of AHSV-VP2 (MVA-VP2) are able to consistently induce
VNAb responses, cell-mediated immunity and protection against
virulent challenge, both in a mouse model and in the equine species
(Alberca et al., 2014; Castillo-Olivares et al., 2011; Chiam et al., 2009;
Manning et al., 2017). Furthermore, we demonstrated that anti-AHSV
Fig. 5. Viraemia of vaccinated mice following AHSV challenge. Titres of AHSV-4 in blood of immunized and non-immunized mice were determined at speciﬁc
time points after challenge. Each point represents the individual virus titres of each animal.
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protective immunity elicited by MVA-VP2 vaccination is associated
mainly, although probably not exclusively, with the induction of VNAb
(Calvo-Pinilla et al., 2014, 2015).
In this paper, we studied the factors that determined the im-
munogenicity of MVA-VP2 vaccines. Speciﬁcally, we studied how the
pre-formed VP2 that is present in the MVA-VP2 vaccine inoculum and
VP2 that is de novo synthesised within cells of the MVA-VP2 vaccinated
host inﬂuence the induction of VNAb and protection. Our results
showed that MVA-VP2 induced immunity relies strongly on the levels of
the protein that are delivered to the immune system at the time of
vaccination and that both sources of VP2 played a role in the MVA-VP2
vaccine immunogenicity. Thus, all the MVA-VP2 vaccine preparations
that contained pre-formed VP2 in their inoculum induced VNAb and
protection against disease and viraemia. Protection levels were reduced
when the levels of VP2 were reduced or absent in the inoculum of live
MVA-VP2 vaccines (at a dose of 107 pfu/mouse). However, the pro-
tective capacity was restored when the inoculum of such vaccines was
supplemented with pre-formed VP2, as was observed in the case of mice
vaccinated with MVA-VP2 (SGP) + MVA-VP2 (UV) or MVA-VP2
(SGP) + MVA-VP2 (HI).
However, sterile immunity was only induced by MVA-VP2 (live)
vaccines, which contain pre-formed VP2 and also express VP2 in host
cells following vaccination. The maximum level of protection in MVA-
VP2 (live) vaccinates could be explained by the highest VNAb titres
reached by these animals at the time of challenge. We determined
previously (Calvo-Pinilla et al., 2014, 2015) that protection against
AHSV in MVA-VP2 vaccinated mice correlated strongly with VNAb ti-
tres at the time of challenge. It is also possible that in the present study
the induction of cell-mediated immune responses by MVA-VP2 vacci-
nation contributed to the highest level of protective immunity achieved
by MVA-VP2 (live), since previous experiments showed that when ad-
ministered as a live vaccine, MVA-VP2 inoculation induces partially
protective cell mediated immune responses (Calvo-Pinilla et al., 2014).
Additionally, the expression of VP2 within host cells is likely to best
preserve the native epitope structure of the protein and its conforma-
tional VNAb epitopes. This is unlikely to occur in the pre-formed VP2 of
the MVA-VP2's inoculum. Indeed, the VP2 protein in the inoculum of
MVA-VP2 (HI) and MVA-VP2 (UV) vaccines was subjected to physical
treatments that were likely to have aﬀected VP2's tertiary structure.
Any of the mechanisms alluded to above could only occur if ex-
pression of VP2 within cells of the MVA-VP2 vaccinated host actually
took place. In the ﬁrst experiment described in this paper, a dose of
107 pfu of MVA-VP2 (SGP) induced very low levels of VNAb (just below
a titre of 10) and it was not clear whether the MVA-VP2 im-
munogenicity depended exclusively on pre-formed VP2 present in the
inoculum. However, in the dose-response experiment we showed that
increasing doses of MVA-VP2 (SGP) correlated with increasing VNAb
titres in the vaccinates sera. This strongly suggests that VP2 is expressed
from within host cells and is eﬀectively processed and presented to the
immune system to induce VNAb and possibly cell-mediated immunity.
Therefore, it can be concluded that both pre-formed VP2 in the in-
oculum and de novo expression of VP2 from MVA-VP2 infected cells of
the vaccinated host contributed to the induction of the highly protec-
tive immune response of MVA-VP2 vaccination, but that if administered
in a puriﬁed form, MVA-VP2 would need to be administered at higher
doses than when it is administered as a crude lysate.
With regards to the reduced immunogenicity observed in mice
vaccinated with MVA-VP2 (SGP) vaccine, it is worth noting that other
poxvirus vector vaccines are formulated with an adjuvant (Draper et al.,
2008). Thus, Carbopol, an eﬃcacious adjuvant for the equine species, is
used to formulate Canarypox-based vaccines for equine inﬂuenza,
herpesvirus and West Nile virus (Draper and Heeney, 2010; El Garch
et al., 2008; Minke et al., 2006, 2007). Notably, a prototype vaccine
against AHS based on Canarypox was also formulated with this ad-
juvant (Guthrie et al., 2009). The exact mechanisms by which Carbopol
exerts its adjuvant eﬀect on this type of vaccine are not known, but it is
possible that these eﬀects can also be replicated in the case of MVA-VP2
vaccines.
The observations made in our study open new avenues for im-
proving the eﬃcacy of MVA based vaccines for infectious diseases in
general and for AHSV in particular. Consequently, it would be inter-
esting to test whether improved antibody responses could be achieved
by enhancing the secretion of the antigens from MVA-VP2 infected
cells, which would facilitate B-cell receptor binding of the antigen.
Targeting the MVA-expressed antigens to the extracellular space might
also contribute to preserving the native structure of relevant con-
formational epitopes. In addition, it would also be equally interesting to
examine the importance of the antigen processing and MHC presenta-
tion pathways within host cells infected with MVA vaccines to direct
more eﬀectively the induction of T-cell responses. In previous experi-
ments we showed that the main eﬀector mechanism of immunity of
MVA-VP2 vaccines was mediated by VNAb, though other studies (de la
Poza et al., 2013; El Garch et al., 2012) and the results presented in this
paper suggest cellular immunity could have an important com-
plementary protective role.
The use of recombinant MVA viruses expressing AHSV-VP2 have
been shown to be a suitable approach for developing safe, eﬃcacious
AHS vaccines with DIVA (Diﬀerentiation of Infected from Vaccinated
Animals) capability (Chiam et al., 2009; Castillo-Olivares et al., 2011;
Alberca et al., 2014; Calvo-Pinilla et al., 2015, 2015). Furthermore,
recent studies suggest MVA-VP2 could be used to develop polyvalent
AHS vaccines (Manning et al., 2017), an essential feature if the vaccine
is to be used in an endemic country. MVA-VP2 vaccines could be
manufactured commercially and this largely depends on the ﬁnal de-
sign and formulation of the vaccine which will be determined by some
of the conditions and parameters examined in this study.
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